A Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) Trial of Multiple Ascending Fixed Doses of SAM-531 in Subjects With Mild to Moderate Alzheimer's Disease.
Phase of Trial: Phase II
Latest Information Update: 18 Jan 2010
At a glance
- Drugs Cerlapirdine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Wyeth
- 22 Jun 2008 Patient numbers amended from 78 to 72 as reported by ClinicalTrials.gov.
- 22 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Dec 2007 Status change from initiated to recruiting.